Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs

Cytometry Part A

Volumn 62, Issue 2, 2004, Pages 129-138

  García Escarp, Marta ^a   Martínez Muñoz, Vanessa ^b   Sales Pardo, Irene ^b   Barquinero, Jordi ^a   Domingo, Joan Carles ^b   Marin, Pedro ^b   Petriz, Jordi ^b  

^a BANC DE SANG I TEIXITS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ABCG2; Flow cytometry; Mitoxantrone; R482

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CYCLOSPORIN A; DAUNORUBICIN; DOXORUBICIN; FUMITREMORGIN C; GLYCINE; MITOXANTRONE; MONOCLONAL ANTIBODY; PROBENECID; RHODAMINE 123; SYTO 13; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL;

ARTICLE; CELL KINETICS; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG RESISTANCE; DRUG TRANSPORT; ENZYME SPECIFICITY; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KB CELLS; MUTATION; NEOPLASM PROTEINS; TRANSFECTION;

EID: 9644282891     PISSN: 15524922     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.a.20072     Document Type: Article

References (28)

1. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 1998;58:5337-5339.
2. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, Artursson P. Correlation of gene expression often drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 2001;299:164-170.
3. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van de Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-3464.
4. van den Heuvel-Eibrink MM, Wiemer EA, Prins A, Meijerink JP, Vossebeld PJ, van der Holt B, Pieters R, Sonneveld P. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML). Leukemia 2002;16:833-839.
5. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP, Doyle LA. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 1999;91:429-433.
6. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001;7:1028-1034.
7. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-15670.
8. Ross DD, Karp JE, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000;96:365-368.
9. Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 1987;5:1364-1372.
10. Sargent JM, Williamson CJ, Maliepaard M, Elgie AW, Scheper RJ, Taylor CG. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia. Br J Haematol 2001;115:257-262.
11. Robey RW, Medina-Perez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin Cancer Res 2001;7:145-152.
12. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG, Schellens JH. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999;59:4559-4563.
13. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD, Kohno S. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun 2001;280:1216-1223.
14. Robey RW, Honjo Y, van de Laar A, Miyake K, Regis JT, Litman T, Bates SE. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). Biochim Biophys Acta 2001;1512:171-182.
15. Krishan A, Sauerteig A, Stein JH. Comparison of 3 commercially available antibodies for flow cytometric monitoring of P-glycoprotein expression in tumor-cells. Cytometry 1991;12:731-742.
16. Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein- mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 1992;89:5824-5828.
17. Broxterman HJ, Kuiper CM, Schuurhuis GJ, Tsuruo T, Pinedo HM, Lankelma J. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein. Biochem Pharmacol 1988;37:2389-2393.
18. Mechetner EB, Schott B, Morse BS, Stein WD, Druley T, Davis KA, Tsuruo T, Roninson IB. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci USA 1997;94:12908-1213.
19. Park SW, Lomri N, Simeoni LA, Fruehauf JP, Mechetner E. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Cytometry 2003;53A: 67-78.
20. Krishan A, Fitz CM, Andritsch I. Drug retention, efflux, and resistance in tumor cells. Cytometry 1997;29:279-285.
21. Krishan A. Heterogeneity of anthracycline retention and response to efflux blockers in human tumors. Cytometry 1995;21:72-75.
22. Krishan A. Effect of drug efflux blockers on vital staining of cellular DNA with Hoechst 33342. Cytometry 1987;8:642-645.
23. Krishan A, Sridhar KS, Davila E, Vogel C, Sternheim W. Patterns of anthracycline retention modulation in human-tumor cells. Cytometry 1987;8:306-314.
24. Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for doxorubicin resistance. Cancer Res 2002;62:2294-2299.
25. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, Bates SE. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ ABCP-overexpressing cells. Cancer Res 2001;61:6635-6639.
26. Stein WD, Cardarelli C, Pastan I, Gottesman MM. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates. Mol Pharmacol 1994;45:763-772.
27. Petriz J, Gottesman MM, Aran JM. An MDR-EGFP gene fusion allows for direct cellular localization, function and stability assessment of P-glycoprotein. Curr Drug Deliv 2004;1:43-56.
28. Cardarelli CO, Aksentijevich I, Pastan I, Gottesman MM. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res 1995;55:1086-1091.